Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy. Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions. What would you choose? #ACR21 #ACRBest @RheumNow https://t.co/FywUp3zCj2